Abstract | BACKGROUND:
Bullous pemphigoid is an immunobullous disease affecting predominantly older patients. In severe cases, high-dose corticosteroids and/or other immunosuppressants are often needed long term to control the disease. These can be associated with serious side-effects in this patient population. Objective To evaluate the benefit of plasmapheresis as a steroid saving agent in a cohort of 10 patients. RESULTS: CONCLUSIONS:
|
Authors | C A Egan, K P Meadows, J J Zone |
Journal | International journal of dermatology
(Int J Dermatol)
Vol. 39
Issue 3
Pg. 230-5
(Mar 2000)
ISSN: 0011-9059 [Print] England |
PMID | 10759969
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anti-Inflammatory Agents
- Autoantigens
- Carrier Proteins
- Cytoskeletal Proteins
- DST protein, human
- Dystonin
- Immunoglobulin G
- Immunosuppressive Agents
- Nerve Tissue Proteins
- Non-Fibrillar Collagens
- collagen type XVII
- Cyclophosphamide
- Collagen
- Azathioprine
- Prednisone
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents
(therapeutic use)
- Autoantigens
(immunology)
- Azathioprine
(therapeutic use)
- Carrier Proteins
- Collagen
(immunology)
- Combined Modality Therapy
- Cyclophosphamide
(therapeutic use)
- Cytoskeletal Proteins
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Dystonin
- Evaluation Studies as Topic
- Female
- Humans
- Immunoglobulin G
(blood)
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Nerve Tissue Proteins
- Non-Fibrillar Collagens
- Pemphigoid, Bullous
(pathology, therapy)
- Plasmapheresis
- Prednisone
(therapeutic use)
- Remission Induction
- Severity of Illness Index
- Time Factors
- Treatment Outcome
|